What's Happening?
Myriad Genetics and SOPHiA GENETICS have announced a strategic partnership to develop a global liquid biopsy companion diagnostic test. This collaboration aims to leverage Myriad's laboratory capabilities in the U.S. and SOPHiA GENETICS' extensive network of over 800 institutions worldwide. The focus will initially be on the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDM™, which detects genomic alterations from a single blood draw. The partnership is expected to expand access to innovative oncology testing and lay the foundation for a new hybrid model in companion diagnostics.
Why It's Important?
The collaboration between Myriad Genetics and SOPHiA GENETICS is significant as it could enhance the development and commercialization of comprehensive companion diagnostic solutions. This partnership has the potential to positively impact patient lives by advancing personalized healthcare at scale. By combining the strengths of both companies, the collaboration aims to serve clinical and pharmaceutical partners better, accelerating the adoption of liquid biopsy solutions across key markets. This could lead to improved patient care and lower healthcare costs.
What's Next?
Myriad Genetics will pursue regulatory submissions in the U.S., while SOPHiA GENETICS will manage submissions outside the U.S. Both companies will collaborate on development activities, providing pharmaceutical partners access to key regulated markets globally. They will participate in a panel discussion at the World CB and CDx Summit in Boston to provide further details on the collaboration.
